Drug Trial Radar · NCT05856760
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
May 19, 2023
Primary completion
Oct 14, 2024
Study completion Oct 25, 2024
Sponsor
- Lead sponsor
- Travere Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment for at least 12 weeks prior to study entry
Conditions
- Immunoglobulin A Nephropathy
Interventions
SparsentanDrug
Target dose of 400 mg daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Urine Albumin-creatinine Ratio (UA/C) at Week 24Time frame: Week 24
Locations
30 sites in 2 countries. Site status is shown where the registry gives one.
Travere Investigational Site
Birmingham, Alabama
Travere Investigational Site
Chula Vista, California
Travere Investigational Site
Garden Grove, California
Travere Investigational Site
Glendale, California
Travere Investigational Site
Denver, Colorado
Travere Investigational Site
Boise, Idaho
Travere Investigational Site
Chubbuck, Idaho
Travere Investigational Site
Idaho Falls, Idaho
Travere Investigational Site
Chicago, Illinois
Travere Investigational Site
Evergreen Park, Illinois
Travere Investigational Site
Fort Wayne, Indiana
Travere Investigational Site
Kansas City, Kansas
Travere Investigational Site
Louisville, Kentucky
Travere Investigational Site
Shreveport, Louisiana
Travere Investigational Site
Albuquerque, New Mexico
Travere Investigation Site
Clifton Park, New York
Travere Investigational Site
Fresh Meadows, New York
Travere Investigational Site
New York, New York
Travere Investigational Site
Jacksonville, North Carolina
Travere Investigational Site
New Bern, North Carolina
Travere Investigational Site
Columbus, Ohio
Travere Investigational Site
Philadelphia, Pennsylvania
Travere Investigational Site
Columbia, South Carolina
Travere Investigational Site
Dallas, Texas
Travere Investigational Site
Dallas, Texas
Travere Investigational Site
Hong Kong, Hong Kong
Travere Investigational Site
Kowloon, Hong Kong
Travere Investigational Site
Shatin, Hong Kong
Travere Investigational Site
Sheung Wan, Hong Kong
Travere Investigational Site
Tsuen Wan, Hong Kong
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.